Victory Capital Management
EWTX icon

Victory Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Victory Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.7M Buy
902,870
+113,827
+14% +$3.92M 0.02% 702
2026
Q1 		$24.9M Buy
789,043
+42,481
+6% +$1.23M 0.02% 787
2025
Q4 		$18.5M Buy
746,562
+247,916
+50% +$4.98M 0.01% 881
2025
Q3 		$8.09M Buy
498,646
+55,809
+13% +$792K ﹤0.01% 1182
2025
Q2 		$5.81M Buy
+442,837
New +$6.39M ﹤0.01% 1265
2025
Q1 		– Sell
-21,568
Closed -$576K – 2494
2024
Q4 		$576K Buy
+21,568
New +$687K ﹤0.01% 1992

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Victory Capital Management's EWTX Position: Q2 2026 in Review

Victory Capital Management increased its Edgewise Therapeutics (EWTX) stake by 14% in Q2 2026, buying an estimated $3.92M and bringing the position to 902,870 shares worth $36.7M. The position accounts for 0.02% of the portfolio, ranked #702.

Victory Capital Management first reported a position in EWTX in Q4 2024 and has held it in 6 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Victory Capital Management held 902,870 shares of Edgewise Therapeutics worth $36.7M as of Q2 2026.
  • Victory Capital Management bought 113,827 Edgewise Therapeutics shares in Q2 2026, an estimated $3.92M.
  • Edgewise Therapeutics made up 0.02% of Victory Capital Management's portfolio in Q2 2026, its #702 holding.
  • Victory Capital Management first reported a position in Edgewise Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.